Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 7/20 | 0.38 |
| ▸ | SRC | P12931 | 3/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2618928 | 0.83 | TNK2 (0.52) | PDE1APDE1BPDE1CTNK2SRC | |
| SCHEMBL6938371 | 0.76 | TNK2 (0.52) | TNK2SRCABL1BTKTLR7 | |
| SCHEMBL463424 | 0.75 | BTK (0.50) | TNK2SRCABL1BTKIGF1R | |
| SCHEMBL13541945 | 0.72 | BTK (0.39) | TNK2SRCABL1BTKIGF1R | |
| SCHEMBL8230097 | 0.70 | TNK2 (0.33) | TNK2SRCABL1TLR7 | |
| SCHEMBL13541946 | 0.70 | TNK2 (0.52) | TNK2SRCABL1BTKIGF1R | |
| SCHEMBL19733424 | 0.70 | TNK2 (0.49) | TNK2SRCABL1BTKTLR7 | |
| SCHEMBL31244345 | 0.70 | MTOR (0.46) | TNK2SRCABL1IGF1R | |
| SCHEMBL20962363 | 0.67 | PIK3CD (0.32) | SRCABL1 | |
| SCHEMBL23960263 | 0.67 | BTK (0.46) | TNK2SRCABL1BTKTLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184567-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | PDE1A 990/4885PDE1B 997/4885PDE1C 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.